Publication | Open Access
Real-World Budget Impact of the Adoption of Insulin Glargine Biosimilars in Primary Care in England (2015–2018)
21
Citations
9
References
2020
Year
These results may encourage decision makers in England to promote the use of best-value treatments in primary care and to reevaluate variation across CCGs.
| Year | Citations | |
|---|---|---|
Page 1
Page 1